Skip to main content
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. — Investor Relations & Filings

Ticker · XRTX ISIN · CA98420Q2071 LEI · 254900RAT3XZPF9F9350 US Manufacturing
Open in API
Filings indexed 263 across all filing types
Latest filing 2024-04-30 Regulatory Filings
Country CA Canada
Listing US XRTX

About XORTX Therapeutics Inc.

https://www.xortx.com/

XORTX Therapeutics Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes therapies for diseases associated with aberrant purine metabolism and high serum uric acid. The company's pipeline focuses on progressive kidney diseases, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 2 Diabetic Nephropathy (T2DN), and Acute Kidney Injury (AKI), as well as gout. Its lead program, XRx-008, is in development for the treatment of ADPKD.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1221 characters), and it primarily serves as a regulatory update with an attached press release. According to the rules, such filings that do not contain full reports but are regulatory announcements or attachments fall under Regulatory Filings (RNS).
2024-04-30 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XORTX Therapeutics Inc., pursuant to SEC rules. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The length is short (1221 characters), and the content is primarily an announcement of a press release rather than a full report. According to the rules, such filings are classified as Regulatory Filings (RNS) because they do not contain the full report but rather an announcement or supplementary information.
2024-04-22 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes a press release dated April 8, 2024, attached as Exhibit 99.1. The document length is only 1217 characters, indicating it is a brief filing primarily announcing the press release rather than containing detailed financial data or comprehensive reports. Form 6-K filings typically serve as regulatory filings to disclose material information between annual reports. There is no indication of full financial statements or detailed management discussion. Therefore, this document fits best under Regulatory Filings (RNS) as a general announcement and disclosure filing.
2024-04-08 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1217 characters), and it primarily serves as a regulatory filing to disclose a press release. According to the rules, such filings that do not contain full reports or detailed financial data should be classified as Regulatory Filings (RNS).
2024-04-08 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes an exhibit index listing consolidated financial statements, management discussion and analysis, an annual information form, and CEO and CFO certificates for the year ended December 31, 2023. The document itself is a filing that provides these exhibits but does not contain the full annual report or financial statements within the text. Given the short length (1389 characters) and the nature of the content (a report submission with exhibits), this is best classified as a Regulatory Filing (RNS) rather than the full Annual Report (10-K) or Management Discussion and Analysis (MDA).
2024-04-03 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XORTX Therapeutics Inc., pursuant to SEC rules. It includes a signature page and references an attached press release (Exhibit 99.1) dated March 27, 2024. The document length is only 1221 characters, indicating it is a brief filing rather than a full report. Form 6-K filings typically serve as regulatory announcements for material events or press releases by foreign issuers, not full financial reports or detailed filings. There is no substantive financial data or detailed report content present. Therefore, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2024-03-27 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.